EGFR and non-small cell lung carcinoma: ADAURA was a groundbreaking international study evaluating the efficacy and safety of a third-generation EGFR TKI, Osimertinib, as an adjuvant therapy for patients with completely resected EGFR mutation-positive stage IB to IIIA NSCLC [15].